MedTech Disruptors: Combining Better Patient Outcomes with Direct-to-Consumer Marketing
Published on July 6, 2018
Jim Callinan discusses how these three innovative MedTech firms are leveraging direct-to-consumer marketing to accelerate growth and disrupt their industry.
Technological innovation has always been a cornerstone of the health care industry. Some changes are incremental, while others are revolutionary, but the diagnostic tools and treatment techniques are constantly improving.
Our Emerging Growth Strategy specializes in finding disruptive companies that are able to upend the status quo. We look for firms that are simultaneously able to translate their innovative ideas into better outcomes for their patients and to deliver robust commercial success.
In this article we discuss three of our current holdings, all of which are transforming the industry and are well-positioned for long-term success.
These companies share a common strategy. They all market directly to consumers, bypassing traditional “gatekeepers.” Creating brand awareness drives steeper adoption curves as patients request these products from their providers.
Inogen (INGN) provides portable oxygen systems to patients around the world who require supplemental oxygen. Although it’s a specialty product targeted at a niche market, the company has clearly established itself as the rising star in a growing space. Their market share increased 19% per year from 2012 – 2016, and the addressable market is expanding 7-10% per year as the Baby Boomer generation ages.
The primary reason the company is doing so well is that they have developed a genuinely superior solution to an old problem. Previously, patients who required supplemental oxygen had only two options – a stationary concentrator (pump), which prevents the user from moving, or a so called “portable” oxygen tank, which is cumbersome to use and needs to be replaced constantly.
Inogen manufactures a truly portable concentrator that can be worn as a backpack, drastically improving the quality of life for supplemental oxygen patients. It’s convenient, lightweight, and never needs replacing. Plus, all models are approved for travel by the FAA.
Not surprisingly, it has gained traction quickly. The company has delivered 45.6% revenue CAGR since 2009, and it estimates 2018 revenues will increase to at least $315 million (from $249 in 2017). Much of Inogen’s success is based on its decision to advertise its products directly to consumers rather than rely on traditional, often bureaucratic, channels.
The long term picture looks promising as well. Based on their current trajectory, we estimate they can boost their per unit sales up to 800,000 per year by 2025, up from 128,000 in 2017.
Align Technology (ALGN) develops technology-forward, alternative orthodontic solutions. They are best known for their Invisalign® product, which is a removable, clear plastic teeth straightening device that replaces traditional metal/wire braces. In addition, they have developed intraoral scanning technology, which replaces the traditional stone cast models used to fit orthodontic appliances.
Not surprisingly, the Invisalign system has become quite popular. Patients have enthusiastically embraced the aesthetic benefits, while dental care providers appreciate the convenience and the seamless integration of the digital diagnostics.
The company has experienced robust growth for the past several years. In 2013 it recorded just over 400,000 Invisalign shipments, and in 2017 that figure jumped to just over 900,000 units. At the end of Q1, 2018, they had 5.5 million patients globally, representing a 43% increase year-over-year.
Their market share is growing also. On their current trajectory, we expect they will achieve 30% U.S. market share by 2023 and 20% internationally. Currently it is 17% and 6%, respectively.
Finally, the company has an innovative marketing strategy. In addition to their direct-to-consumer advertising channels, they are also establishing retail stores where prospective patients can walk in and learn more about the Invisalign process. Like Inogen, Align’s strategy of marketing its value proposition directly to consumers has led to increased awareness and a steeper inflection curve. This contrasts with their peer group which markets only to orthodontists and dentists.
The company is in a great position to continue its rapid expansion, and based on their track record we expect them to continue to execute successfully.
Insulet Corporation (PODD) creates high tech insulin delivery systems for patients with diabetes. The key advantage of their product, known as the Omnipod® system, is that it is tubeless and self-contained, meaning it attaches directly to the patient and can be managed remotely from the patient’s mobile phone. Traditional insulin pumps have a much heavier footprint, requiring the patient to wear a catheter that is connected via tubes to a small monitoring/pumping device that the patient must keep on their person at all times.
Like Inogen, Insulet’s solution substantially improves the quality of life for their patients, as they are no longer physically tethered to an external machine. As a result, the company has been experiencing rapid growth for the past several years. Revenues increased from $185 million in 2013 to $464 million in 2017, representing a 20% CAGR.
In addition to their basic Omnipod solution, Insulet is currently expanding their product line to leverage their flexible platform. Through a partnership with Dexcom, they are creating an integrated offering where their pump will automatically dose insulin based on blood glucose levels read by Dexcom’s sensor. This essentially takes human interaction out of the process, thereby creating an artificial pancreas. This system is scheduled to launch sometime in 2020 and we expect it will not only lead to share gains but also grow the category, as 40% of type 1 diabetics still do not use insulin pumps.
We believe there is considerable upside for this firm, based on their high-quality products and their direct-to-consumer marketing efforts. In addition, Insulet is competitively priced, which should further boost sales given the current trend toward high deductible insurance plans. Patients who are paying out of pocket are motivated to find cost-sensitive solutions, particularly if the treatment is better than the alternatives. Given all these factors, we are forecasting their market share to double from 15% in 2018 to 30% by 2023. We also expect their addressable market to increase substantially, as the global incidence of diabetes is projected to double by 2030.
CONCLUSION
We feel each of these companies is an excellent example of a medtech disruptor, and we expect more to emerge in the near-to-medium term. We will continue to carefully monitor the industry to find other attractive investment opportunities.
James Callinan
Chief Investment Officer – Emerging Growth
Featuring
James Callinan
Chief Investment Officer – Emerging Growth
Jim Callinan was the Co-Founder & Chief Investment Officer at RS Investments. He also co-founded the RS Growth Group LLC in 1996 and managed the RS Emerging Growth Fund from 1996 until 2010. In 1999 Mr. Callinan was named Morningstar’s Domestic Stock Manager of the Year.*
He served as portfolio manager for the Putnam OTC Emerging Growth Fund from 1994 to 1996 and began his career at Putnam Investments as an equity research analyst in 1987. He joined Osterweis Capital Management in 2016 and brought with him the Emerging Growth Partners, LP, a concentrated small cap growth strategy he founded at RS in 2006.
Mr. Callinan is a member of the Weatherbie Capital Advisory Board.
He is an equity owner in the firm and the Lead Portfolio Manager for the emerging growth strategy.
Mr. Callinan graduated from Harvard College (B.A. in Economics), New York University (M.S. in Accounting) and Harvard Business School (M.B.A.). Mr. Callinan holds the CFA designation.
*Morningstar Managers of the Year are determined by a combination of qualitative research by Morningstar’s manager research analysts; risk-adjusted medium- to long-term performance track records; and performance in the calendar year.
For more information about this strategy, please send us an email or call us at (800) 700-3316.
Emerging Opportunity Fund Quarter-End Performance (as of 9/30/23)
| 1 MO | QTD | YTD | 1 YR | 3 YR | 5 YR | 7 YR | 10 YR |
INCEP (10/1/2012) |
||
|---|---|---|---|---|---|---|---|---|---|---|
| OSTGX | -5.65% | -7.78% | 10.64% | 13.71% | -0.38% | 6.44% | 12.96% | 10.67% | 13.00% | |
| Russell 2000 Growth Index | -6.60 | -7.32 | 5.24 | 9.59 | 1.09 | 1.55 | 6.77 | 6.72 | 8.86 | |
Gross/Net expense ratio as of 3/31/23: 1.25% / 1.13%. The Adviser has contractually agreed to waive certain fees through June 30, 2024. The net expense ratio is applicable to investors.
Performance data quoted represent past performance; past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance of the Fund may be higher or lower than the performance quoted. Performance data current to the most recent month end may be obtained by calling shareholder services toll free at (866) 236-0050. Performance prior to December 1, 2016 is that of another investment vehicle (the “Predecessor Fund”) before the commencement of the Fund’s operations. The Predecessor Fund was converted into the Fund on November 30, 2016. The Predecessor Fund’s performance shown includes the deduction of the Predecessor Fund’s actual operating expenses. In addition, the Predecessor Fund’s performance shown has been recalculated using the management fee that applies to the Fund, which has the effect of reducing the Predecessor Fund’s performance. The Predecessor Fund was not a registered mutual fund and so was not subject to the same operating expenses or investment and tax restrictions as the Fund. If it had been, the Predecessor Fund’s performance may have been lower.
Rates of return for periods greater than one year are annualized.
Where applicable, charts illustrating the performance of a hypothetical $10,000 investment made at a Fund’s inception assume the reinvestment of dividends and capital gains, but do not reflect the effect of any applicable sales charge or redemption fees. Such charts do not imply any future performance.
The Russell 2000 Growth Index (Russell 2000G) is a market-capitalization-weighted index representing the small cap growth segment of U.S. equities. This index does not incur expenses, is not available for investment and includes the reinvestment of dividends.
References to specific companies, market sectors, or investment themes herein do not constitute recommendations to buy or sell any particular securities.
There can be no assurance that any specific security, strategy, or product referenced directly or indirectly in this commentary will be profitable in the future or suitable for your financial circumstances. Due to various factors, including changes to market conditions and/or applicable laws, this content may no longer reflect our current advice or opinion. You should not assume any discussion or information contained herein serves as the receipt of, or as a substitute for, personalized investment advice from Osterweis Capital Management.
Complete holdings of all Osterweis mutual funds (“Funds”) are generally available ten business days following quarter end. Holdings and sector allocations may change at any time due to ongoing portfolio management. Fund holdings as of the most recent quarter end are available here: Emerging Opportunity Fund
Opinions expressed are those of the author, are subject to change at any time, are not guaranteed and should not be considered investment advice.
Mutual fund investing involves risk. Principal loss is possible. The Osterweis Emerging Opportunity Fund may invest in unseasoned companies, which involve additional risks such as abrupt or erratic price movements. The Fund may invest in small and mid-sized companies, which may involve greater volatility than large-sized companies. The Fund may invest in IPOs and unseasoned companies that are in the early stages of their development and may pose more risk compared to more established companies. The Fund may invest in ETFs, which involve risks that do not apply to conventional funds. Higher turnover rates may result in increased transaction costs, which could impact performance. From time to time, the Fund may have concentrated positions in one or more sectors subjecting the Fund to sector emphasis risk. The Fund may invest in foreign and emerging market securities, which involve greater volatility and political, economic and currency risks and differences in accounting methods. These risks may increase for emerging markets.
Return on equity is the amount of net income returned as a percentage of shareholders equity.
The compound annual growth rate (CAGR) is the mean annual growth rate of an investment over a specified period of time longer than one year.
The Osterweis Funds are available by prospectus only. The Funds’ investment objectives, risks, charges and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the Funds. You may obtain a summary or statutory prospectus by calling toll free at (866) 236-0050, or by visiting www.osterweis.com/statpro. Please read the prospectus carefully before investing to ensure the Fund is appropriate for your goals and risk tolerance.
Osterweis Capital Management is the adviser to the Osterweis Funds, which are distributed by Quasar Distributors, LLC. [33379]
